Revenue

Beyond a 23% profit surge, ILCO's latest results reveal a blueprint for resilience through strategic IPOs, dividends, and a diversified portfolio.

Dillon Consulting's partnership with DNA isn't just M&A; it's a strategic play to build a national architectural force rooted in community and Indigenous partnership.

The Commanders have their builders, but as DC's largest private investment takes shape, a stark question emerges: Who will truly pay for and profit from this mega-project?

Mike Tyson's cannabis brand lands in the Ocean State, partnering with local grower Reborn Roots. A deep dive into the strategy behind entering a tight market.

It's not just about investing in AI. A new study reveals companies detailing specific deployments in filings see 8% more revenue growth. Here's why.

Neonode's Q2 report shows shrinking revenue and widening losses, but a massive jump in MultiSensing® license sales points to a deliberate, high-stakes bet on the automotive sector.

With a top-tier sponsorship, DiamondLake signals its arrival in institutional blockchain. But do its financials and unfinalized deals support the hype?

eClerx brings back early leader Hoshi Mistry to steer its Customer Experience unit, signaling a strategic push to fuse institutional knowledge with AI innovation.

With Coco Gauff and Taylor Fritz, ŌURA isn't just selling a smart ring. It's selling a new philosophy of athletic success built on data, recovery, and story.

As HSDT prepares to report Q2 results, investors are watching closely. Is its unique strategy of tying shareholder value directly to the Solana ecosystem paying off?

Haoxi Health announces a second reverse split in three months, a move to save its Nasdaq listing that investors see as a red flag, despite its strategic AI push.

Cineverse is betting it can solve CTV's ad waste problem by turning podcast ads into TV spots. A deep dive into the tech, the strategy, and the $12M question.

A new composition of matter patent extends protection for Alterity's lead drug to 2045, de-risking its path in MSA and opening a new front against Parkinson's.

Early data for Sutro Biopharma's STRO-004 offers a glimmer of hope for advanced cancer patients. We look at the tech, the trials, and the financial tightrope.

With revenue up 23%, Rubicon Organics invests heavily in new facility tech, temporarily squeezing profits to fuel its bid for long-term global dominance.

As Firehouse Subs opens its 1,500th store, we analyze its unique model blending franchisee success, a $115M mission, and RBI's strategic backing.

A new AI agent from Assort Health is automating the chaotic patient referral process, promising to recover lost revenue and get patients to care faster.

With breakthrough dialysis data and a new heart-mending vessel, Humacyte is balancing radical innovation with commercial reality. Is this the future of medicine?

A new partnership aims to bring the first FDA-approved, oral ketamine pill for depression to your home, using AI and real-world data to ensure safety.

Magna5's fourth consecutive Inc. 5000 ranking is celebrated, but the real story is a blueprint for survival and growth in a volatile digital economy.